Pharmacologic profiling of patient-derived xenograft models of primary treatment-naïve triple-negative breast cancer

Reid T. Powell(Texas A&M Health Science Center), Helen Piwnica‐Worms(Centre for Cancer Biology), Christopher P. Vellano(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Xinhui Zhou(Guangxi Academy of Agricultural Science), Shirong Cai(Sun Yat-sen University), Virginia Giuliani(The University of Texas MD Anderson Cancer Center), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), XiaoYan Ma(The University of Texas MD Anderson Cancer Center), Gloria V. Echeverria(Baylor College of Medicine), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Ningping Feng(The University of Texas MD Anderson Cancer Center), Abena B. Redwood(The University of Texas MD Anderson Cancer Center), Clifford Stephan(Texas A&M Health Science Center), Peter J. Davies(Texas A&M Health Science Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Lei Guo(Hunan Provincial Center for Disease Control and Prevention), Yuan Qi(The University of Texas MD Anderson Cancer Center), Yan Jiang(Southwest University), Xuan Liu(Fudan University), Stacy Moulder(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Yizheng Tu(The University of Texas MD Anderson Cancer Center), Jeffrey T. Chang(Tufts University)
Scientific Reports
October 21, 2020
Cited by 22


Related Papers